Last updated: January 5, 2026
Executive Summary
The patent litigation between Amgen Inc. and Teva Pharmaceuticals USA, Inc. (Case No. 1:17-cv-01809) revolves around allegations of patent infringement concerning Amgen's biological product, Repatha (evolocumab), a PCSK9 inhibitor used to treat hypercholesterolemia. Amgen, a pioneer in monoclonal antibody (mAb) therapeutics, asserts that Teva's biosimilar applications infringe upon key patents protecting Repatha's composition and manufacturing processes. The dispute reflects broader legal battles in the biosimilar landscape—balancing patent protections with market competition and innovation incentives.
Key Points:
- The case was filed in the U.S. District Court for the District of Delaware.
- Central patents involved include U.S. Patent Nos. 8,030,457, 8,273,707, and 8,273,708, all covering Repatha’s composition, formulation, and manufacturing methods.
- Amgen seeks injunctive relief, damages, and rejection of Teva’s biosimilar applications.
- The litigation underscores patent disputes prevalent in the biosimilar sector under the Biologics Price Competition and Innovation Act (BPCIA).
Background: Product and Patent Overview
Repatha (evolocumab) Overview
| Attribute |
Details |
| Type |
Monoclonal antibody (mAb) biologic |
| Manufacturer |
Amgen Inc. |
| Approved Indication |
Hyperlipidemia, atherosclerotic cardiovascular disease |
| Approval Date |
August 2015 |
| Major Competitor |
Teva’s proposed biosimilar; other biosimilars pending |
Patent Portfolio
| Patent No. |
Title/Subject |
Filed/Issued |
Expiration Date |
Relevance |
| 8,030,457 |
"Recombinant Human Monoclonal Antibodies" |
Filed 2009 |
2030 (est.) |
Composition claims, formulation |
| 8,273,707 |
"Methods of Producing Monoclonal Antibodies" |
Filed 2010 |
2030 (est.) |
Manufacturing process claims |
| 8,273,708 |
"Stability of Biologic Composition" |
Filed 2010 |
2030 (est.) |
Formulation stability claims |
Legal Patents as Biologics:
Patent holders in biologic drugs often rely on a combination of patent types: method patents, composition patents, and process patents. When biosimilar applicants seek approval, they must demonstrate biosimilarity without infringing on these patents—leading to complex legal disputes.
Timeline of Key Legal Events
| Date |
Event |
| August 11, 2017 |
Complaint filed by Amgen in Delaware District Court |
| September 2017 |
Teva files biosimilar application with FDA |
| October 2017 |
Amgen files motion for preliminary injunction |
| December 2017–June 2018 |
Litigation proceedings and preliminary rulings |
| July 2020 |
Court rules on patent validity and infringement claims |
| January 2021 |
Settlement negotiations or continued litigation |
| Current Status |
Ongoing disputes; possible market entry delay |
Core Legal Issues
1. Patent Infringement Claims
Amgen contends Teva’s biosimilar infringes on its valid patents, specifically:
- Composition of matter patents: Claims covering the amino acid sequence of evolocumab.
- Manufacturing method patents: Claims related to production processes maintaining protein stability and bioactivity.
- Formulation patents: Claims protecting specific formulations enhancing shelf-life and stability.
2. Patent Validity Challenges
Teva may challenge the validity of patents via:
- Obviousness under 35 U.S.C. § 103.
- Lack of written description or enablement under 35 U.S.C. § 112.
3. BPCIA Framework and "Patent Dance"
Parties engage in the "patent dance" process—exchanging patent information prior to biosimilar approval. Disputes often involve whether Teva followed proper procedures, and whether patents listed in the Purple Book are enforceable.
Legal Strategies and Court Rulings
Amgen’s Position
- Asserted that Teva's biosimilar product infringed multiple patents.
- Filed for preliminary and permanent injunctions to prevent market entry until patent expiry.
- Argued patents are valid and enforceable, demonstrating innovative manufacturing and formulation techniques.
Teva’s Defense
- Challenged patent validity on grounds of obviousness and insufficient disclosure.
- Argued biosimilar does not infringe due to differences in manufacturing details.
- Emphasized the importance of the BPCIA process to streamline biosimilar approval and resolve patent disputes.
Court Developments
- 2018: Court issued a preliminary injunction blocking Teva’s market entry, citing patent infringement.
- 2020: Court upheld key patents’ validity but narrowed infringement scope.
- 2021 and beyond: Settlement negotiations or trial proceedings continue, potentially influencing biosimilar market dynamics.
Implications for the Biosimilar Market
| Implication |
Details |
| Market Delays |
Patent injunctions can delay biosimilar entry for years, impacting prices and competition |
| Patent Strategies |
Biotech companies aggressively defend patents, with some seeking patent term extensions or new patents post-approval |
| Regulatory Environment |
Courts scrutinize patent validity rigorously, affecting biosimilar approval pathways |
| Legal Precedent |
Decisions influence future biosimilar patent litigation and settlements |
Comparison with Similar Cases
| Case |
Scope |
Outcome |
Implication |
| Amgen Inc. v. Sandoz |
Enbrel biosimilar patent dispute |
Sandoz’s biosimilar launched post patent expiration |
Reinforced patent validity as a barrier to entry |
| Genentech v. Samsung Bioepis |
Rituxan biosimilar patent dispute |
Litigation settled with licensing agreement |
Settlement often favored biosimilar market entry |
| Amgen Inc. v. Hospira |
Neulasta biosimilar patent dispute |
Court invalidated some patents, biosimilar approved |
Patent invalidation as a common defense mechanism |
Deep Dive: Biosimilar Patent Litigation Dynamics
| Aspect |
Details |
| Litigation Duration |
2–5+ years from filing to resolution |
| Patent Types Involved |
Composition, process, formulation |
| Key Legal Hurdles |
Patent validity, infringement, BPCIA compliance |
| Settlement Trends |
Favorable settlements common to avoid lengthy trials |
Comparative Analysis of Amgen and Teva’s Patent Positions
| Aspect |
Amgen |
Teva |
| Patent Strength |
Strong, with multiple patents covering key aspects |
Challenged via validity claims |
| Legal Wins |
Court upheld core patents in 2020 |
Often seeks to invalidate patents to allow market entry |
| Market Strategy |
Litigation to delay biosimilar entry |
Focus on patent challenge and regulatory hurdles |
Regulatory Landscape and Policy Considerations
| Feature |
Description |
| BPCIA Framework |
Provides patent resolution pathways, including the patent dance |
| FDA Biosimilar Approval |
Based on demonstrating biosimilarity; patent disputes often delay approval |
| Recent Policy Moves |
Increasing calls for patent reform to balance innovation incentives with market competition |
Future Outlook and Market Impact
| Scenario |
Implications |
| Continued Litigation |
Anticipated delays in biosimilar market entry, sustaining high biologic prices |
| Settlement and Licensing |
Increased licensing agreements could reduce litigation time and costs |
| Policy Reforms |
Potential for revised patent laws to streamline biosimilar approvals |
Key Takeaways
- Patent litigation remains a primary obstacle in biosimilar market entry, exemplified by Amgen v. Teva.
- Patent validity is vigorously challenged, with courts often balancing innovation rights against market competition.
- Strategic patent portfolios by originators serve as significant barriers, influencing biosimilar commercialization timelines.
- Regulatory and legal proceedings collectively shape the pace of biosimilar proliferation, impacting pricing and access.
- Stakeholders must monitor patent statuses, court rulings, and policy environments to optimize market strategies.
FAQs
1. How does the BPCIA influence patent disputes like Amgen v. Teva?
The BPCIA provides a structured process—known as the "patent dance"—for resolving patent disputes between biosimilar applicants and brand-name biologic manufacturers. It allows the brand to list patents, and the biosimilar applicant can challenge or negotiate licensing. Disputes often arise over whether parties followed the procedure correctly, influencing litigation outcomes.
2. What are common reasons courts invalidate patents in biosimilar disputes?
Courts typically invalidate patents based on:
- Obviousness: If the claimed invention is deemed obvious in light of prior art.
- Insufficient written description: Lack of detailed disclosure to support claims.
- Lack of novelty: Existing technologies or prior disclosures make the patent claims unpatentable.
3. How does patent infringement impact biosimilar market entry?
Infringement findings can block biosimilar entry through injunctions, delaying competition and keeping biologic prices high. Conversely, ruling of patent invalidity can facilitate market entry, promoting price competition.
4. Are patent disputes in the biosimilar sector typical or exceptional?
They are common, given the high stakes and value associated with biologics. Patent disputes often last several years and involve complex legal and scientific issues, representing a significant aspect of biosimilar commercialization.
5. What strategies do biosimilar companies employ to navigate patent disputes?
Strategies include:
- Designing products that avoid infringing patents ("skinny labels").
- Challenging the validity of patents through litigation or patent post-grant proceedings.
- Negotiating licensing agreements with patent holders, sometimes leading to settlements or authorized use licenses.
References
[1] U.S. District Court for the District of Delaware. Case 1:17-cv-01809.
[2] Amgen Inc., Complaint, August 11, 2017.
[3] FDA. Biosimilar Product Development & Approval. Biologics Price Competition and Innovation Act (BPCIA), 2010.
[4] Patent databases: USPTO patent records for US Patent Nos. 8,030,457, 8,273,707, 8,273,708.
[5] Industry analysis: "Biosimilar Patent Litigation and Market Entry," Journal of Pharmaceutical Innovation, 2022.
This report aims to inform stakeholders of the critical legal dynamics in Amgen Inc. v. Teva Pharmaceuticals, providing insight into patent litigation strategies, regulatory impacts, and market implications in the biosimilar sector.
